



**Scientist / Associate Scientist, Cancer Immunotherapy**  
**Job Code 414BY**

**Description**

Fate Therapeutics is seeking a highly motivated scientist/associate scientist specialized in immunology and immunotherapy to participate in the discovery of next-generation off-the-shelf induced pluripotent stem cell (iPSC)-derived CAR-T (CAR-iT) cell therapeutic products. The successful candidate will leverage Fate's best-in-class iPSC platform to develop and investigate novel modalities to enhance CAR-iT cell performance in vitro and in vivo and will conduct such activities in collaboration with multiple internal and external groups, including academic leaders in the field of immunotherapy. Prior independent research experience with T cell development, T cell signal transduction or cancer immunotherapy is highly preferred. This is a full-time bench-level position reporting to a Scientist and is located at our corporate headquarters in San Diego, CA.

**Responsibilities**

- Differentiate and evaluate off-the-shelf, iPSC-derived CART cells with in vitro assays (including cytokine release/degranulation and short/long-term killing assay and RNA-seq) and in vivo murine models.
- Investigate, develop and implement novel strategies for next-generation off-the-shelf CAR-iT cell discovery.
- Plan, coordinate and conduct original and independent research with precise data analysis, interpretation, and communication capability and deliver results in a timely manner.
- Participate in daily laboratory maintenance activities including ordering and maintaining stocks of lab reagents.
- Present results in a multidisciplinary team environment that includes collaborations with top research laboratories and pharmaceutical companies.

**Qualifications**

- PhD degree in Immunology, Cancer Biology, Cell Biology or related fields with 0-2 years of relevant experience, or M.S. degree in Biology or related fields with 4+ years relevant experience, or B.S. degree in Biology or related fields with 8+ years of years relevant experience, preferably in a biotech setting.
- Proven track record of leading or contributing to projects in immunology, cancer biology or cell biology.
- In-depth experience with multi-parameter flow cytometry is a must, preferably 8+ color.
- Extensive aseptic technique and mammalian cell culture experience with a minimal of 3 years of hands-on experience is a must.
- Positive outlook, willingness to learn and contribute, and a team-oriented attitude is a must.



- Experience with immune cell functional assays and gene editing of T cells by transfection or transduction is a plus.
- Experience with human CAR-T cells is a plus.
- Knowledge on T cell development, T cell signal transduction, or cellular immunotherapy in oncology is a plus.
- Knowledge with single-cell RNA-seq analysis and bulk RNA-seq analysis is a plus.

### **Working Conditions and Physical Requirements**

- Will require working with cells and cell lines of human and/or animal origin
- Will require working with hazardous materials
- 100% on-site work at corporate headquarters in San Diego, CA
- Evening and weekend work as necessary

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: [careers@fatetherapeutics.com](mailto:careers@fatetherapeutics.com) and reference job code 414BY.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).